Spyre Therapeutics (SYRE) Operating Leases (2019 - 2023)

Spyre Therapeutics (SYRE) has 5 years of Operating Leases data on file, last reported at $3.8 million in Q1 2023.

• For the quarter ending Q1 2023, Operating Leases fell 14.42% year-over-year to $3.8 million; the trailing twelve-month figure through Mar 2023 stood at $3.8 million (down 14.42% YoY), and the FY2022 full-year result was $4.0 million, down 13.11% from the prior year.
• Operating Leases for Q1 2023 stood at $3.8 million, down from $4.0 million in the prior quarter.
• Across five years, Operating Leases topped out at $5.1 million in Q4 2020 and bottomed at $372000.0 in Q1 2019.
• The 5-year median for Operating Leases is $4.7 million (2019), against an average of $4.4 million.
• The widest annual swing landed in 2020, when Operating Leases soared 1194.35%; it then retreated 14.42% in 2023.
• A 5-year view of Operating Leases shows it stood at $4.7 million in 2019, then climbed by 8.85% to $5.1 million in 2020, then dropped by 10.16% to $4.6 million in 2021, then declined by 13.11% to $4.0 million in 2022, then retreated by 4.52% to $3.8 million in 2023.
• The last three Operating Leases figures came in at $3.8 million (Q1 2023), $4.0 million (Q4 2022), and $4.2 million (Q3 2022), per Business Quant data.

Peer Comparison